
Ginkgo Bioworks Investor Relations Material
Latest events

Q1 2025
Ginkgo Bioworks
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Ginkgo Bioworks Holdings Inc
Access all reports
Ginkgo Bioworks Holdings, Inc, a biomolecular engineering company, develops biological manufacturing technologies to program cells for molecular manufacturing systems. Ginkgo Bioworks Holdings software engineering platform uses the widely used programming language Python and its library of bioinformatics functions and statistical methods. Ginkgo Bioworks' programs are designed to modify bacterial genes to make organic compounds such as vanillin, scents to produce civetone in bacteria, Beta-carotene and lycopene in yeast cells, gluconic acid in E. coli; and shikimic acid and artemisinic acid in yeast cells. The company sells its products to pharmaceutical companies including AstraZeneca Group and Eli Lilly & Co; chemical companies including Firmenich SA; flavor, aroma, and fragrance companies; craft breweries; and others.
Key slides for Ginkgo Bioworks Holdings Inc


Q1 2025
Ginkgo Bioworks Holdings Inc


Q3 2024
Ginkgo Bioworks Holdings Inc
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
DNA
Country
🇺🇸 United States